I believe that if they had more competitive pricing on their products here in the states especially, this would not be in the news right now. Just my 2 cents.
Novo's shares have plunged since hitting a record-high in June last year as competition, particularly from U.S. rival Eli Lilly (LLY.N), makes inroads into its market share and as its pipeline of new drugs has failed to impress investors.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.